(Boursier.com) — Euroapi announces the start of an essential collaboration with SpiroChem, a leading Contract Research Organization (CRO), among the best in the field of ‘R&D’ of early-stage chemical processes (route scouting – search for synthetic routes). SpiroChem’s head office is located in Basel, Switzerland.
SpiroChem and EUROAPI join forces to offer their customers a consolidated CRO-CDMO solution, ensuring that the constraints of small molecule industrialization are integrated from the initial drug design stage, thereby accelerating the process.
Customers of both companies will benefit from SpiroChem’s cutting-edge expertise and innovative route scouting solutions, as well as EUROAPI’s industrialization strategy of developing the best synthesis routes taking into account the feasibility of scaling, quality, regulatory and environmental requirements, as well as economic viability. The agreement will further differentiate the value proposition of the two companies, with their customers benefiting from both SpiroChem’s premium early-stage services, and EUROAPI’s capabilities and skills in development and production according to good manufacturing practices .
“By adding a renowned CRO partner such as SpiroChem to our existing ‘R&D’ and industrial offering, this successful collaboration will strengthen our market position and accelerate our CDMO roadmap,” said Cécile Maupas, Director of CDMO at EUROAPI. “In addition to EUROAPI’s manufacturing technologies, SpiroChem’s recognized skills in the field of synthetic pathways will allow us to provide our customers with integrated personalized solutions, so that the development of their chemistry-based drugs is faster, more environmentally friendly and less expensive.”
©2024 Boursier.com